Posted by Michael Wonder on 04 Apr 2022
Bluebird Bio has serious cash flow concerns; inability to strike reimbursement deals in Europe partly to blame
3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic disorders and cancers.
Abruptly, the company exited the European market last year. Evidently, this is because the company couldn’t strike deals with payers for its EMA approved gene therapies, Zynteglo (betibeglogene autotemcel; dubbed beti-cel) and Skysona (elivaldogene autotemcel; called eli-cel).
